Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type  2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial

ConclusionPatients with T2D reported higher treatment satisfaction with once-weekly tirzepatide (5, 10, and 15  mg) compared with dulaglutide 0.75 mg after 52 weeks of treatment.Trial RegistrationClinicalTrials.gov, NCT03861052.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research